Page 37 - PRECONGRESS COURSE 06

Key Points 4
 There are considerable differences between different recombinant as well as between different urinary preparations in terms of bio potency
 FSH Receptor variants are not only associated with higher endogenous FSH serum concentrations but these women also need more exogenous FSH during COH
 Albeit the observed differences in endogenous FSH levels and the need for higher amounts of exogenous FSH in COH cycles clinical pregnancy rates are not different between these groups of patients
 There are no obvious clinically relevant differences between urinary and recombinant FSH preparations in terms of neither clinical nor in terms of ongoing pregnancy. Moreover, life birth rates are also not different.
 Stimulation protocols using sequential regimens starting with with acidic isoforms of FSH and switching towards more basic isoforms of FSH might be more efficient compared to protocols using either acidic or basic isoforms only in terms of biochemical, clinical and ongoing pregnancy rates.
ESHRE PCC 6:
Ovarian Stimulation for IVF: Individualization and beyond:
The stimulation drug FSH: What do we need to know?
TAKE HOME MESSAGES
Page 33 of 258
PRECONGRESS COURSE 06 I GENEVA, SWITZERLAND – 2 JULY 2017 37